Plasma Metabolomics of Intermediate and Neovascular Age-Related Macular Degeneration Patients

Código QR

Plasma Metabolomics of Intermediate and Neovascular Age-Related Macular Degeneration Patients

To characterize metabolites and metabolic pathways altered in intermediate and neovascular age-related macular degeneration (IAMD and NVAMD), high resolution untargeted metabolomics was performed via liquid chromatography-mass spectrometry on plasma samples obtained from 91 IAMD patients, 100 NVAMD...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sabrina L. Mitchell, Chunyu Ma, William K. Scott, Anita Agarwal, Margaret A. Pericak-Vance, Jonathan L. Haines, Dean P. Jones, Karan Uppal, Milam A. Brantley
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	age-related macular degeneration IAMD NVAMD metabolomics acylcarnitines carnitine shuttle Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/1988585a959e449fb6547ea6a03ac1c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Biochemical Markers for the Diagnosis of Mitochondrial Fatty Acid Oxidation Diseases
por: Pedro Ruiz-Sala, et al.
Publicado: (2021)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

Medium & long-chain acylcarnitine’s relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study
por: Dan-meng Zheng, et al.
Publicado: (2021)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty D, et al.
Publicado: (2021)

Circulating monocytes and B-lymphocytes in neovascular age-related macular degeneration
por: Hector SM, et al.
Publicado: (2017)

Associations of ARMS2 and CFH Gene Polymorphisms with Neovascular Age-Related Macular Degeneration
por: Supanji S, et al.
Publicado: (2021)

The burden of neovascular age-related macular degeneration: a patient’s perspective
por: Spooner KL, et al.
Publicado: (2018)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi S, et al.
Publicado: (2021)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner K, et al.
Publicado: (2017)

Agreement of swept-source and spectral-domain optical coherence-tomography retinal thickness measurements in neovascular age-related macular degeneration
por: Hanumunthadu D, et al.
Publicado: (2017)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017)

Implantation of the First IMT Macular Lens in Age-Related Macular Degeneration (Literature Review)
por: M. M. Bikbov, et al.
Publicado: (2019)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat D, et al.
Publicado: (2020)

Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
por: Michelle Prasuhn, et al.
Publicado: (2021)

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
por: Phan LT, et al.
Publicado: (2021)

Plasma C-C Chemokine Concentrations in Intermediate Age-Related Macular Degeneration
por: Alan G. Palestine, et al.
Publicado: (2021)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida DRP, et al.
Publicado: (2021)

Early and intermediate age-related macular degeneration: update and clinical review
por: García-Layana A, et al.
Publicado: (2017)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Jing Wang, et al.
Publicado: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

The Anti-Inflammatory Effect of Hydrogen Gas Inhalation and Its Influence on Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular Age-Related Macular Degeneration
por: I-Chia Liang, et al.
Publicado: (2021)

Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration
por: Sobolewska B, et al.
Publicado: (2021)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Optimized Prediction Models from Fundus Imaging and Genetics for Late Age-Related Macular Degeneration
por: Arun Govindaiah, et al.
Publicado: (2021)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
por: Muste JC, et al.
Publicado: (2021)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Comparison of choroidal neovascularization secondary to white dot syndromes and age-related macular degeneration by using optical coherence tomography angiography
por: Wang JC, et al.
Publicado: (2018)

Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
por: Antaki F, et al.
Publicado: (2021)

Microcurrent stimulation in the treatment of dry and wet macular degeneration
por: Chaikin L, et al.
Publicado: (2015)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel PJ, et al.
Publicado: (2017)